ASTRAZENECA ANNOUNCES NON-EXECUTIVE BOARD CHANGES

17 February 2015

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to
shareholders for election as a Non-Executive Director at the Company's Annual
General Meeting (AGM) on 24 April 2015.  On election, the Board also proposes
appointing Dr Bargmann to AstraZeneca's Science Committee.

Cori is the Torsten N. Wiesel Professor and head of the Lulu and Anthony Wang
Laboratory of Neural Circuits and Behavior at The Rockefeller University, New
York, and a Howard Hughes Medical Institute investigator.

John Varley, senior independent Non-Executive Director and Dame Nancy Rothwell,
Non-Executive Director, both intend to retire from the Board at the close of the
AGM on 24 April 2015, each having served as a Board member for nine years. John
is currently Chairman of the Remuneration Committee and a member of the
Nomination and Governance Committee.  Dame Nancy Rothwell is currently Chairman
of the Science Committee, and a member of the Remuneration Committee and the
Nomination and Governance Committee.

As a result of the retirement of John Varley and Dame Nancy Rothwell, the
following Board Committee changes will take place with effect from the close of
the AstraZeneca 2015 AGM:

·  Rudy Markham will become senior independent Non-Executive Director.

·  Graham Chipchase will become Chairman of the Remuneration Committee and
     a member of the Nomination and Governance Committee.

·  Bruce Burlington will become Chairman of the Science Committee and a member
     of the Nomination and Governance Committee.

·  Geneviève Berger will oversee sustainability matters on behalf of the Board.

In addition, Shriti Vadera will become a member of the Remuneration Committee
with immediate effect.

Leif Johansson, AstraZeneca Chairman, said: "John Varley and Dame Nancy Rothwell
have been committed and hard-working Board members, serving the Company and its
shareholders for the best part of a decade. I would like to pay tribute to their
experience, wisdom, common sense and collegiality, as well as their leadership
of the Remuneration Committee and the Science Committee respectively. I speak
for all of my colleagues on the Board in saying that we will miss them and their
contribution to our work; they go with our very best wishes for their future
endeavours."

"Their retirement has provided us with an opportunity to propose the appointment
of new Board members. We welcomed Ann Cairns last year and are delighted that
Cori Bargmann has agreed to join the Board in April. Cori will bring a wealth of
experience in scientific research, fitting the needs of AstraZeneca's Board very
well."

All other current Directors will be presenting themselves for re-election at the
AGM, in accordance with AstraZeneca's normal practice.

In making the proposals and Board Committee appointments described above, the
Board considered and satisfied itself as to the availability and time commitment
of the Directors concerned.

In relation to the proposed election of Cori Bargmann as a Non-Executive
Director, there are no directorships to disclose under paragraph (1) and no
disclosure obligations arise under paragraphs (2) to (6) of LR 9.6.13 R of the
UK Listing Authority's Listing Rules.

-ENDS-

NOTES TO EDITORS

Dr Cori Bargmann - biographical details

Dr Cori Bargmann is the Torsten N. Wiesel Professor and head of the Lulu and
Anthony Wang Laboratory of Neural Circuits and Behavior at The Rockefeller
University, New York.  She has been a Howard Hughes Medical Institute
investigator since 1995.  She is a neurobiologist who studies the relationships
between genes, neural circuits and behaviour using C. elegans, a tiny roundworm,
as the model for her work.  Many of the genes and neural pathways in C. elegans
are similar to those of mammals and their study provides an insight into the
development and functioning of neural circuits.

Cori holds a degree in biochemistry from the University of Georgia and a Ph.D.
from the Massachusetts Institute of Technology, where she studied oncogenes with
Robert Weinberg.  She pursued a postdoctoral fellowship with H. Robert Horvitz
at MIT until 1991, when she accepted a faculty position in the Department of
Anatomy at the University of California, San Francisco, spending 13 years there,
latterly as Vice-Chair of the department.  She took up her current position at
The Rockefeller University in 2004.

Cori is the recipient of the 2015 Benjamin Franklin Medal in Life Science, one
of nine individuals who will be presented with awards by The Franklin Institute,
Philadelphia this year.  The award is for her contributions to neurobiology that
have led to major discoveries elucidating the relationship between genes,
neurons, neural circuits and behaviour.

Membership of AstraZeneca Board Committees, with effect from the close of the
AGM on 24 April 2015

Audit Committee
Rudy Markham (Chairman of the Committee)
Bruce Burlington
Ann Cairns
Jean-Philippe Courtois
Shriti Vadera

Remuneration Committee
Graham Chipchase (Chairman of the Committee)
Leif Johansson
Rudy Markham
Shriti Vadera

Nomination and Governance Committee
Leif Johansson (Chairman of the Committee)
Bruce Burlington
Graham Chipchase
Rudy Markham

Science Committee
Bruce Burlington (Chairman of the Committee)
Cori Bargmann
Geneviève Berger
Marcus Wallenberg

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler      +44 20 7604 8030
                      (UK/Global)
Vanessa Rhodes        +44 20 7604 8037
                      (UK/Global)
Ayesha Bharmal        +44 20 7604 8034
                      (UK/Global)
Jacob Lund            +46 8 553 260 20
                      (Sweden)
Michele Meixell       + 1 302 885 6351
                      (US)

Investor Enquiries
Thomas Kudsk Larsen   +44 20 7604 8199  mob: +44 7818 524185
Karl Hård             +44 20 7604 8123  mob: +44 7789 654364
Eugenia Litz          +44 20 7604 8233  mob: +44 7884 735627
Craig Marks           +44 20 7604 8591  mob: +44 7881 615764
Christer Gruvris      +44 20 7604 8126  mob: +44 7827 836825